Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update

Strengthened financial position with the approval of TWYMEEG® (Imeglimin hydrochloride) for the treatment of type 2 diabetes in Japan: Allowed Poxel to draw the third and final tranche of the IPF loan for EUR 13.5 million - included in the Q2 cash ...

Full "IntellAsia: Resources" article